Heat shock proteins protect the barrier function of epithelial cell lines

1998 ◽  
Vol 114 ◽  
pp. A368
Author(s):  
H. Feldhaar ◽  
J. Ries ◽  
W.F. Caspary ◽  
J. Stein
2019 ◽  
Vol 73 ◽  
pp. 563-571
Author(s):  
Joanna Jakubowicz-Gil ◽  
Roman Paduch ◽  
Krystyna Skalicka-Woźniak ◽  
Joanna Sumorek-Wiadro ◽  
Adrian Zając ◽  
...  

Aim: The aim of the present study was to investigate the efficacy of osthole (7-metoxy-8-isopenthenocoumarin) alone and combined with tamoxifen (TAM) in the elimination of human cervical cancer cells via programmed death. The involvement of heat shock proteins, i.e. well-known molecular chaperones, will be investigated. Material/Methods: Three human cervical cancer cell lines, infected with human papilloma virus (HPV), i.e. HeLa (HPV 18), SiHa (HPV 16), and CaSki (HPV 16 and 18), were used in the experiments. After osthole and TAM treatment, cells stained with fluorochromes were analyzed microscopically according to apoptotic, autophagic, and necrotic morphology. Hsp27, Hsp72, and Hsp90 levels were analyzed by immunoblotting. Transfection with specific siRNA was used for blocking of Hsp expression. Results: In the HeLa, CaSki, and SiHa cell lines, osthole and TAM applied alone had no significant effect on cell death induction. This was correlated with an overexpression of heat shock proteins 27, 72, and 90. In the case of a combination of both drugs, the level of apoptosis was elevated only in SiHa cells. Preincubation with osthole followed by TAM addition as well as simultaneous incubation with both drugs was the most effective. This was correlated with the inhibition of Hsp27, Hsp72, and Hsp90 expression. Blocking of Hsp expression with specific siRNA increased the sensitivity of the studied cell lines to the induction of apoptosis, but not to autophagy or necrosis. Conclusions: Our results indicated that the elimination of heat shock proteins from cervical cancer cells sensitized them to initiation of apoptosis after osthole and tamoxifen treatment.


1994 ◽  
Vol 87 (1) ◽  
pp. 39-46 ◽  
Author(s):  
Hideki Matsumoto ◽  
Mari Shimura ◽  
Tokunori Omatsu ◽  
Kumio Okaichi ◽  
Hideyuki Majima ◽  
...  

2007 ◽  
Vol 103 (4) ◽  
pp. 1344-1354 ◽  
Author(s):  
Cristina Zanini ◽  
Giuliana Giribaldi ◽  
Giorgia Mandili ◽  
Franco Carta ◽  
Nicoletta Crescenzio ◽  
...  

Author(s):  
Lucas A. Rigo ◽  
Cristiane S. Carvalho-Wodarz ◽  
Adriana R. Pohlmann ◽  
Silvia S. Guterres ◽  
Nicole Schneider-Daum ◽  
...  

Author(s):  
SHIN-YA NAKAGAWA ◽  
KEIJI MATSUDA ◽  
TOMOYA NAKANO ◽  
GANESH CHANDRA JAGETIA ◽  
JUN-ICHI ASAUMI ◽  
...  

2000 ◽  
Vol 182 (2) ◽  
pp. 231-235 ◽  
Author(s):  
Susanna Paju ◽  
Florence Goulhen ◽  
Sirkka Asikainen ◽  
Daniel Grenier ◽  
Denis Mayrand ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (18) ◽  
pp. 3880-3889 ◽  
Author(s):  
Jianfei Qian ◽  
Sungyoul Hong ◽  
Siqing Wang ◽  
Liang Zhang ◽  
Luhong Sun ◽  
...  

Abstract Tumor cell–derived heat shock proteins are used as vaccines for immunotherapy of cancer patients. However, current approaches require the generation of custom-made products and are clinically ineffective. To improve the applicability of heat shock protein–based immunotherapy in cancers and to enhance clinical efficacy, we explored combinational treatments in a myeloma setting using pooled heterogeneous or allogeneic myeloma cell line–derived glycoprotein 96 (gp96) as universal vaccines, and clearly demonstrated that pooled but not single gp96 from heterogeneous or allogeneic myeloma cell lines was as effective as autologous gp96 in protecting mice from tumor challenge and rechallenge and in treating established myeloma. We showed that interferon γ and CD4+ and CD8+ T cells were required for gp96-induced antimyeloma responses and that pooled gp96 induced broader immune responses that protected mice from developing different myeloma. Furthermore, pooled gp96 plus CpG in combination with anti-B7H1 or anti–interleukin-10 monoclonal antibodies were effective in treating mice with large tumor burdens. Thus, this study strongly suggests that pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines from autologous tumors for immunotherapy and induce immune responses against broader tumor antigens that may protect against tumor recurrence and development of unrelated tumors in vaccinated myeloma patients.


2015 ◽  
Vol 3 (4) ◽  
pp. e12355 ◽  
Author(s):  
Hao-Yu Liu ◽  
Stefan Roos ◽  
Hans Jonsson ◽  
David Ahl ◽  
Johan Dicksved ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document